Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | Real-world: efficacy of everolimus + exemestane HR+, HER2- BC

Michael Gnant • 14 May 2020
ESMO Breast 2020
Breast Cancer Everolimus Exemestane
BOLERO-2

Michael Gnant, MD, Vienna General Hospital, Vienna, Austria, discusses the STEPAUT study, a non-interventional study, evaluating the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Michael Gnant

5:07
What is the role of CDK4/6 inhibitors in early breast cancer?
Michael Gnant • 6 Jun 2023
2:27
NeoALTTO: HER2/CEP17 ratio as a predictive biomarker in HER2+ breast cancer
Michael Gnant • 8 Jun 2023
7:05
Late recurrences in ER-positive breast cancer and the challenges it poses for treatment
Michael Gnant • 8 Jun 2023
3:42
RxPONDER: is it all OFS?
Michael Gnant • 8 Dec 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals